Partners Seek to Develop New Imagining Agents for Cardiovascular Disease Diagnosis
By MedImaging International staff writers Posted on 09 Dec 2013 |
Partners in a recently signed research agreement will be developing new imaging agents for the noninvasive measurement of blood flow in the heart for the diagnosis of cardiovascular diseases–a sector worth of some two billion USD annually.
Hadasit (Jerusalem, Israel), the technology transfer company of the Hadassah Medical Organization (Jerusalem, Israel) announced the initiation of a three-year license and cooperation agreement with Synektik SA (Warsaw, Poland) to develop new imagining agents for use in PET/CT scans, which will enable the quantitative measurement of blood flow to the heart. The potential agents are expected to enable the clinician to determine the extent of damage resulting from a heart attack, and predict the degree of recovery after the heart attack or bypass surgery.
Research will be conducted at the Hadassah Medical Organization in Jerusalem in cooperation with Synektik's new research and development facility in Warsaw. Development funding of four million USD will be provided by Synektik, which will receive a worldwide license for any newly developed imaging agent and will spearhead further development, clinical trials registration, and commercialization.
Dr. Eyal Mishani, director of the cyclotron and radiochemistry unit of the Hadassah Medical Organization, said, "The funding would facilitate pre-clinical research and development stages and preparation for clinical trials which will be performed jointly with Synektik."
Related Links:
Hadasit
Hadassah Medical Organization
Synektik SA
Hadasit (Jerusalem, Israel), the technology transfer company of the Hadassah Medical Organization (Jerusalem, Israel) announced the initiation of a three-year license and cooperation agreement with Synektik SA (Warsaw, Poland) to develop new imagining agents for use in PET/CT scans, which will enable the quantitative measurement of blood flow to the heart. The potential agents are expected to enable the clinician to determine the extent of damage resulting from a heart attack, and predict the degree of recovery after the heart attack or bypass surgery.
Research will be conducted at the Hadassah Medical Organization in Jerusalem in cooperation with Synektik's new research and development facility in Warsaw. Development funding of four million USD will be provided by Synektik, which will receive a worldwide license for any newly developed imaging agent and will spearhead further development, clinical trials registration, and commercialization.
Dr. Eyal Mishani, director of the cyclotron and radiochemistry unit of the Hadassah Medical Organization, said, "The funding would facilitate pre-clinical research and development stages and preparation for clinical trials which will be performed jointly with Synektik."
Related Links:
Hadasit
Hadassah Medical Organization
Synektik SA
Latest Industry News News
- Bayer and Google Partner on New AI Product for Radiologists
- Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement
- IBA Acquires Radcal to Expand Medical Imaging Quality Assurance Offering
- International Societies Suggest Key Considerations for AI Radiology Tools
- Samsung's X-Ray Devices to Be Powered by Lunit AI Solutions for Advanced Chest Screening
- Canon Medical and Olympus Collaborate on Endoscopic Ultrasound Systems
- GE HealthCare Acquires AI Imaging Analysis Company MIM Software
- First Ever International Criteria Lays Foundation for Improved Diagnostic Imaging of Brain Tumors
- RSNA Unveils 10 Most Cited Radiology Studies of 2023
- RSNA 2023 Technical Exhibits to Offer Innovations in AI, 3D Printing and More
- AI Medical Imaging Products to Increase Five-Fold by 2035, Finds Study
- RSNA 2023 Technical Exhibits to Highlight Latest Medical Imaging Innovations
- AI-Powered Technologies to Aid Interpretation of X-Ray and MRI Images for Improved Disease Diagnosis
- Hologic and Bayer Partner to Improve Mammography Imaging
- Global Fixed and Mobile C-Arms Market Driven by Increasing Surgical Procedures
- Global Contrast Enhanced Ultrasound Market Driven by Demand for Early Detection of Chronic Diseases